by Peter Ciszewski | Apr 30, 2021
Jonathan Troost, PhD, from the Michigan Institute for Clinical and Health Research at the University of Michigan, discusses the statistical analysis that determined if proteinuria is a viable outcome measure for focal segmental glomerulosclerosis (FSGS). FSGS...
by Peter Ciszewski | Apr 30, 2021
Michael Hayden, MBChB, PhD, CEO of Prilenia Therapeutics and a Killam Professor at the University of British Columbia, discusses the PROOF-HD trial. The PROOF-HD trial is testing the safety and efficacy of pridopidine in patients with early stage Huntington...
by Peter Ciszewski | Apr 29, 2021
Florence Wong, MD, Professor of Medicine at the University of Toronto, gives an overview of hepatorenal syndrome type 1 (HRS-1). As Dr. Wong explains, HRS-1 is a life-threatening syndrome involving acute kidney failure in patients with cirrhosis and ascites. It...
by Peter Ciszewski | Apr 27, 2021
Howard Trachtman, MD, Pediatric Nephrologist at NYU Langone Health provides an overview of focal segmental glomerulosclerosis (FSGS). FSGS is a heterogeneous kidney disorder best defined as glomerular histopathology. Patients with FSGS typically present with a...
by Peter Ciszewski | Apr 23, 2021
Jennifer Ibrahim, MD, Head of North America Medical Affairs, Rare Disease at Sanofi Genzyme, discusses the human genome project and how it has been used to shorten the diagnostic journey for rare disease patients. The human genome project was an international...
